Stagezero covered by Refinitiv Stock Reports Plus On September 20th, Refinitiv issues a stock report on SZLS, that goes over the company fundamentals, peer comparison, analysts reports, etc. While some sections of the reports (like analysts ratings) are missing some data due to the lack of visibility of Stagezero, it's still great to have such reports on the company, and the report is really good as well.
The average score for SZLS is 7 (4-7 is neutral, 8-10 is positive), and is based on Earnings, Fundamental, Relative Valuation, Risk and Price Momentum. That rating is awesome considering where we are with the stock price and the price action of the last months.
What really stands out in the report is the fundamentals report for the company, which is rated 10/10 (Profitability, Debt, Earnings Quality, Dividend), and is probably tthe reason why they issued a report on Stagezero. The report highlights the revenue growth of 3157% this year.
A large part of these reports is generated by data analysis, and there is no mention (or consideration) of the recent acquisition of Care Oncology.